FOR STAFF: Hospital doctors, GPs, specialist nursing staff and clinical pharmacists

PATIENT GROUP: Adult patients with Child Pugh B or C cirrhosis who are experiencing symptoms which interfere with their quality of life

REFERENCES AND RELATED DOCUMENTS


University Hospitals Bristol NHS Foundation Trust. End of Life Care Tool


---

**AUTHORISING BODY**

British Association for the Study of the Liver End of Life Special Interest Group and British Hepatology Pharmacy Group

**AUTHORS**

Hazel Woodland, Janki Jethwa, Bonita Stevens and Sarah Case

**CONTRIBUTERS**

Hepatology Department, University Hospitals Bristol NHS Foundation Trust

Supportive and Palliative Care Team, University Hospitals Bristol NHS Foundation Trust

Clinical Pharmacy Team, University Hospitals Bristol NHS Foundation Trust

The British Hepatology Pharmacy Group - Paul Selby, Maria Isabella Bonacini, Stuart Hill and Tina Shah

Fiona Finlay, Queen Elizabeth University Hospital Glasgow

King's College Hospital Palliative Medicine and Clinical Pharmacy Teams

**SAFETY**

Evidence in this field is limited. Suggested doses and dosing intervals are based largely on expert opinion and may differ from standard end of life prescribing guidelines, but are felt to be a safe starting point.

**QUERIES**

Contact the BASL secretariat on [Samantha@basl.org.uk](mailto:Samantha@basl.org.uk)